Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

ketorolac intranasal (Rx)Brand and Other Names:Sprix

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

intranasal

  • 15.75mg per 100 microL spray; 8 sprays/1.7g bottle
more...

Pain

Indicated for short-term (up to 5 days) management of moderate to moderately severe pain

<65 years: 31.5 mg (ie, 1 spray in each nostril) q6-8h; not to exceed 126 mg/day

<50 kg or ≥65 years: 15.75 mg (ie, 1 spray in only 1nostril) q6-8h; not to exceed 63 mg/day

Renal Impairment

1 spray (15.75 mg) in 1 nostril

Total dose: 15.75 mg intranasal q6-8hr; not to exceed 4 doses (63 mg/day)

Hepatic Impairment

Use caution; may cause elevation of liver enzymes; discontinued if symptoms of liver toxicity develop

Administration

Store refrigerated until use, then may keep at room temperature during use

Discard bottle within 24 hr after first dose, even if bottle still contains medication (will not deliver intended dose after 24 hr)

Safety and efficacy not established

Next

Interactions

Interaction Checker

ketorolac intranasal and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Nasal discomfort (15%)

            Rhinalgia (13%)

            1-10%

            Increased lacrimation (5%)

            Throat irritation (4%)

            Oliguria (3%)

            Rash (3%)

            Bradycardia (2%)

            Decreased urine output (2%)

            Increased ALT and/or AST (2%)

            Hypertension (2%)

            Rhinitis (2%)

            Previous
            Next

            Warnings

            Black Box Warnings

            Limitations of use

            • Total duration of use of intranasal alone or sequentially with and other ketorolac formulations should not exceed 5 days

            Cardiovascular risk

            • NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal; risk may increase with duration of use; patients with risk factors for or existing cardiovascular disease may be at greater risk; contraindicated for perioperative pain in the setting of CABG surgery (increased risk of MI and stroke)

            Gastrointestinal risk

            • NSAIDs increase risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal; GI adverse events may occur at any time during use and without warning symptoms; elderly patients are at greater risk for serious GI events

            Bleeding risk

            • Inhibits platelet function and is contraindicated with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding

            Renal risk

            • Contraindicated with advanced renal impairment and patients at risk for renal failure due to volume depletion

            Contraindications

            Hypersensitivity to ketorolac, other NSAID, aspirin, ethylenediamine tetraacetic acid (EDTA)

            Active peptic ulcer disease, recent GI bleeding or perforation, or history of peptic ulcer disease or GI bleeding

            History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs

            Prophylactic analgesic before any major surgery; during the perioperative period in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease or patients at risk for renal failure due to volume depletion

            Labor and delivery

            Breastfeeding women

            Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or those for whom hemostasis is critical

            Coadministration with probenecid or pentoxifylline

            Cautions

            May lead to onset of new hypertension or exacerbate existing hypertension

            NSAIDs may cause serious skin reactions (eg, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis)

            Common local adverse effects include mild and transient nasal discomfort and irritation

            Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include the elderly, or those with impaired renal function, hypovolemia, heart failure, liver dysfunction, salt depletion, and individuals taking diuretics, ACE inhibitors, or ARBs

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C prior to 30 weeks gestation; D starting at 30 weeks gestation, risk of premature closure of ductus arteriosus near term

            The Quebec Pregnancy Registry identified 4705 women who had spontaneous abortions by 20 weeks' gestation; each case was matched to 10 control subjects (n=47,050) who had not had spontaneous abortions; exposure to nonaspirin NSAIDs during pregnancy was documented in approximately 7.5% of cases of spontaneous abortions and in approximately 2.6% of controls. (CMAJ, September 6, 2011; DOI:10.1503/cmaj.110454)

            Lactation: Distributed in human breast milk, caution not advised

            Limited data from 1 published study involving 10 breastfeed women 2-6 days postpartum showed low levels of ketorolac in breast milk; levels were undetectable (<5 ng/mL) in 4 of the patients

            After a single 10 mg dose, the maximum milk concentration observed was 7.3 ng/mL, and the maximum milk to plasma ratio was 0.037; after 1 day of dosing (10 mg q6hr), the maximum milk concentration was 7.9 ng/mL, and the maximum milk-to-plasma ratio was 0.025

            Assuming an infant daily intake of 400-1000 mL/day and a maternal body weight of 60 kg, the calculated maximum daily infant exposure was 0.00263 mg/kg/day, which is 0.4% of the maternal weight adjusted dose

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhibits synthesis of prostaglandins in body tissues by inhibiting at least 2 cyclooxygenase isoenzymes, cyclooxygenase-1 (COX-1) and -2 (COX-2)

            May inhibit chemotaxis, may alter lymphocyte activity, decrease proinflammatory cytokine activity, and may inhibit neutrophil aggregation.  These effects may contribute to its anti-inflammatory activity

            Pharmacokinetics

            Bioavailability: 60% (compared with 30 mg IM)

            Peak plasma time: 0.75 hr  

            Peak plasma concentration: 1805.8 ng/mL

            Protein bound: 99% (5% to albumin)

            Vd: 13 L

            Metabolism: By liver via hydroxylation and conjugation

            Half-life: 5.24 hr; 6-19 hr with renal impairment 

            Excretion: 92% urine (~40% as metabolites); 6% feces

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.